Literature DB >> 2644929

The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more.

R Klein1, B E Klein, S E Moss, M D Davis, D L DeMets.   

Abstract

The four-year incidence and progression of retinopathy were investigated in a population-based sample of people with diabetes diagnosed at 30 years of age or older. For insulin users, 73 (47%) of the 154 who did not have any retinopathy at the first visit developed it in the four-year interval, and 31 (7%) of the 418 free of proliferative retinopathy developed it. Worsening of retinopathy occurred in a total of 34% (142/418). For nonusers of insulin, corresponding rates were 34% (110/320) for incidence of any retinopathy, 2% (11/486) for developing proliferative retinopathy, and 25% (121/486) for worsening. These population-based data clearly indicate the risk of retinopathy worsening in a short interval (four years) in a large proportion of people with older-onset diabetes, a group previously thought to be relatively protected from retinopathy. Such patients who make up the largest proportion of diabetic patients in the United States need examination when diabetes is first diagnosed and regular follow-up.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644929     DOI: 10.1001/archopht.1989.01070010250031

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  67 in total

1.  Laser treatment of diabetic retinopathy.

Authors:  P E Tornambe
Journal:  West J Med       Date:  1992-10

2.  Prevalence of Diabetic Retinopathy in Western Indian Type 2 Diabetic Population: A Hospital - based Cross - Sectional Study.

Authors:  Piyush Rameshchandra Ramavat; Manish Rameshchandra Ramavat; Balaji Wasudeo Ghugare; Rohini G Vaishnav; Manjiri Uttam Joshi
Journal:  J Clin Diagn Res       Date:  2013-06-01

3.  Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy.

Authors:  B M Ben-Mahmud; W H Chan; R M Abdulahad; A Datti; A Orlacchio; E M Kohner; R Chibber
Journal:  Diabetologia       Date:  2006-07-11       Impact factor: 10.122

4.  Crossing the evidence chasm: building evidence bridges from process changes to clinical outcomes.

Authors:  David C Kendrick; Davis Bu; Eric Pan; Blackford Middleton
Journal:  J Am Med Inform Assoc       Date:  2007-02-28       Impact factor: 4.497

5.  Requisite models for strategic commissioning: the example of type 1 diabetes.

Authors:  Mara Airoldi; Gwyn Bevan; Alec Morton; Mónica Oliveira; Jenifer Smith
Journal:  Health Care Manag Sci       Date:  2008-06

Review 6.  Japanese Clinical Practice Guideline for Diabetes 2016.

Authors:  Masakazu Haneda; Mitsuhiko Noda; Hideki Origasa; Hiroshi Noto; Daisuke Yabe; Yukihiro Fujita; Atsushi Goto; Tatsuya Kondo; Eiichi Araki
Journal:  Diabetol Int       Date:  2018-03-27

7.  Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits.

Authors:  Hiten G Sheth; Sher Aslam; Nigel Davies
Journal:  BMJ       Date:  2006-05-27

8.  Diabetic Retinopathy: Focus on Minority Populations.

Authors:  Arpine Barsegian; Boleslav Kotlyar; Justin Lee; Moro O Salifu; Samy I McFarlane
Journal:  Int J Clin Endocrinol Metab       Date:  2017-11-11

9.  Blood-retinal barrier permeability and its relation to progression of retinopathy in patients with type 2 diabetes. A four-year follow-up study.

Authors:  J Cunha-Vaz; E Leite; J C Sousa; J R de Abreu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-03       Impact factor: 3.117

10.  Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis.

Authors:  Tien Y Wong; Mkaya Mwamburi; Ronald Klein; Michael Larsen; Harry Flynn; Marisol Hernandez-Medina; Gayatri Ranganathan; Barbara Wirostko; Andreas Pleil; Paul Mitchell
Journal:  Diabetes Care       Date:  2009-12       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.